ARTICLE | Company News
J&J, Akebia deal
February 24, 2017 2:17 AM UTC
Johnson & Johnson’s Janssen Pharmaceutica N.V. company granted Akebia exclusive, worldwide rights to develop and commercialize a portfolio of preclinical inflammatory bowel disease small molecules tha...
BCIQ Target Profiles